A Phase 3 interventional study of Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain and Acetylsalicylic Acid (Aspirin, BAYE4465) in Common Cold, Pharyngitis and Tonsillitis, sponsored by Bayer. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Common Cold with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Common Cold · Russian Federation.
Among the 13 studies in Common Cold with a site in Russian Federation, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2004, is one of 8 in phase 3, and was the 1st registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →1 of the 13 studies in Common Cold with a site in Russian Federation is open now. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,088 is above the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 250 across the 11 interventional studies, 140 across the 2 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 4 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 5 studies filed under Common Cold — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Common Cold with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the analgesic efficacy of a single dose of a fixed combination of 500 mg Aspirin (Acetylsalicylic Acid) and 4 mg Lidocaine in adult patients with sore throat associated with a common cold in comparison to a single treatment with 500 mg Aspirin or 4 mg Lidocaine alone as well a Placebo (treatment without any active ingredient). The combination of Aspirin and Lidocaine in a single lozenge is expected to provide relief from sore throat pain by sequential action. A very fast inset of action will be achieved by the locally acting Lidocaine and a long duration of action will be achieved by the systemically acting Aspirin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Drug: Lidocain
Drug: Placebo
Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
Single oral application of Aspirin (as lozenge)
Single oral application of Lidocain (as lozenge)
Single oral application of Placebo (as lozenge)
Sum of pain intensity differences SPID
Time frame: 120 minutes
Pain intensity difference to baseline (PID12 min)
Time frame: 12 minutes
Pain intensity difference to baseline (PID120 min)
Time frame: 120 minutes
Pain intensity difference to baseline (PID)
Time frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose
Total pain relief to baseline (TOTPAR)
Time frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose
Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)
Time frame: 60, 120, 180, and 240 minutes post dose
Overall assessment of treatment
Time frame: 240 minutes
Assessment of safety and tolerability
Time frame: 240 minutes
Ran from Nov 2004 to primary completion in May 2005, 5 months.
Of 17 phase 3 interventional studies under Common Cold, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin